Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study

Acta Diabetologica

Volumn 52, Issue 4, 2015, Pages 727-732

  Morano, Susanna ^a   Romagnoli, Elisabetta ^a   Filardi, Tiziana ^a   Nieddu, Luciano ^b   Mandosi, Elisabetta ^a   Fallarino, Mara ^a   Turinese, Irene ^a   Dagostino, Mariangela Pia ^c   Lenzi, Andrea ^a   Carnevale, Vincenzo ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NINT University   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Abdominal ultrasonography; Deep fat; Echocardiography; Glucagon like peptide 1 receptor agonists; Subcutaneous fat; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP FAT DEPOSIT; DOPPLER ECHOGRAPHY; DRUG EFFECT; ECHOGRAPHY; FAT THICKNESS; FEMALE; HUMAN; KIDNEY ARTERY; LIPID STORAGE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESISTIVE INDEX; SHORT COURSE THERAPY; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADIPOSE TISSUE; AGED; AGONISTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOCARDIOGRAPHY; FOLLOW UP; METABOLISM; RISK FACTOR; TIME FACTOR;

ADIPOSE TISSUE; ADULT; AGED; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; PEPTIDES; RISK FACTORS; TIME FACTORS; ULTRASONOGRAPHY; VENOMS;

EID: 84932642569     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0710-z     Document Type: Article

References (35)

1. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ, on the behalf of the LEAD-2 and LEAD-3 Study Groups (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163–1172
2. De Fronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092–1100
3. Kim D, MacConell L, Zhuang D, Kothare PA, Trautman M, Fineman M, Taylor K (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487–1493
4. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30:1608–1610
5. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analysis of randomised controlled trials. BMJ 344:d7771. doi:10.1136/bmj.d7771
6. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C (1995) Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 141:1128–1141
7. Chaston TB, Dixon JB (2008) Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systemic review. Int J Obes 32:619–628
8. Després JP (2011) Excess visceral adipose tissue/ectopic fat. J Am Coll Cardiol 57:1887–1889
9. Bazzocchi A, Diano D, Ponti F, Salizzoni E, Albisinni U, Marchesini G, Battista G (2014) A 360-degree overview of body composition in healthy people: relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. Nutrition 30:696–701
10. Kawai T, Kamide K, Onishi M, Yamamoto-Hanasaki H, Baba Y, Hongyo K, Shimaoka I, Tatara Y, Takeya Y, Ohishi M, Rakugi H (2011) Usefulness of the resistive index in renal Doppler ultrasonography as an indicator of vascular damage in patients with risks of atheroscerosis. Nephrol Dial Transplant 26:3256–3262
11. Società Italiana di Diabetologia—Associazione Medici Diabetologi (2014) Standard italiani per la cura del diabete mellito. http://www.standarditaliani.it
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
13. Suzuki R, Watanabe S, Hirai Y, Akiyama K, Nishide T, Matsushima Y, Murayama H, Ohshima H, Shinomiya M, Shirai K, Saito Y, Yoshida S, Saisho H, Ohto M (1993) Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med 95:309–314
14. Kawasaki S, Aoki K, Hasegawa O, Numata K, Tanaka K, Shibata N, Shimada S, Okamura A, Terauchi Y (2008) Sonographic evaluation of visceral fat by measuring para- and perirenal fat. J Clin Ultrasound 36:129–133
15. Sabir N, Sermez Y, Kazil S, Zencir M (2001) Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound 14:121–128
16. Sperandeo M, Varriale A, D’Amico G, Sperandeo G, Piattelli ML, De Cata A, Greco A, Prigigallo F, Annese MA, Cedrone L, Vendemiale G (2007) Intrarenal resistive index in patients with type 2 diabetes mellitus with and without microalbuminuria. Eur J Inflamm 5:103–110
17. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F (2003) Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 88:5163–5168
18. Sperandeo M, Carnevale V, Muscarella S, Sperandeo G, Varriale A, Filabozzi P, Piattelli ML, D’Alessandro V, Copetti M, Pellegrini F, Dimitri L, Vendemiale G (2011) Clinical application of transthoracic ultrasonography in patients with pneumonia. Eur J Clin Invest 41:1–7
19. Bagger JI, Christensen M, Knop FK, Vilsbøl T (2011) Therapy for obesity based on gastrointestinal hormones. Rev Diabet Stud 8:339–347
20. Holst JJ, Deacon CF (2013) Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab 24:145–152
21. Sever MJ, Kocjan T, Pfeifer M, Kravos NA, Janez A (2014) Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 170:451–459
22. Tchernof A, Despres JP (2013) Pathophysiology of human visceral obesity: an update. Physiol Rev 93:359–404
23. Bartelt A, Heeren J (2014) Adipose tissue browning and metabolic health. Nat Rev Endocrinol 10:24–36
24. Liu KH, Chan JL, Chan WB, Chan JCN, Chu CWW (2006) Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 29:379–384
25. Liu J, Fox CS, Hickson DA, May WD, Hairston KG, Carr JJ, Taylor HA (2010) Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 95:5419–5426
26. Cetin DC, Nasr G (2014) Obesity in the elderly: more complicated than you think. Clev Clin J Med 81:51–61
27. Christensen DL, Faurholt-Jepsen D, Faerch K, Mwaniki DL, Boit MK, Kilonzo B, Tetens I, Friis H, Borch-Johnsen K (2014) Insulin resistance and beta-cell function in different ethnic groups in Kenya: the role of abdominal fat distribution. Acta Diabetol 51:53–60
28. The Emerging Risk Factors Collaboration (2011) Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 377:1085–1095
29. Ross R, Bradshaw AJ (2009) The future of obesity reduction: beyond weight loss. Nat Rev Endocrinol 5:319–326
30. Iacobellis G, Singh N, Wharton S, Sharma AM (2008) Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity 16:1693–1697
31. Kim MK, Tomita T, Kim MJ, Sasai H, Maeda S, Tanaka K (2009) Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol 106:5–11
32. Bazzocchi A, Filonzi G, Ponti F, Amadori M, Sassi C, Salizzoni E, Albisinni U, Battista G (2013) The role of ultrasonography in the evaluation of abdominal fat: analysis of technical and methodological issues. Acad Radiol 20:1278–1285
33. Iacobellis G, Corradi D, Sharma AM (2005) Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2:536–543
34. Lorber D (2013) GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 31:238–249
35. Bacchi E, Negri C, Tarperi C, Baraldo A, Faccioli N, Milanese C, Zanolin ME, Lanza M, Cevese A, Bonora E, Schena F, Moghetti P (2014) Relationships between cardiorespiratory fitness, metabolic control, and fat distribution in type 2 diabetes subjects. Acta Diabetol 51:369–375